Alnylam Pharmaceuticals, Inc. ranks in an above-average position in its peer group, with a broadly solid profile across the main structural dimensions. The market setup has weakened, with clear trend damage and relative performance under pressure.
Innovation Premium Without Stability Buffer
52w drawdown -55.4% · 21d vs sector -27.3%
Peer-relative scores, weakest to strongest
Alnylam Pharmaceuticals develops RNA interference therapies targeting genetic and rare diseases.
The market prices ALNY’s stock to capture an innovation premium, rewarding expansion and AI-driven initiatives rather than business resilience. With revenue growth of 74% year-on-year (Q2 2026, sector-leading momentum), ALNY trades at levels that reflect high expectations for its RNAi focus, extensive AI partnerships, and willingness to shoulder heavy royalty obligations—factors that set it apart from other biotechs. This results in 54% one-year volatility (well above peer median, high risk) and significant price swings when setbacks or regulatory hurdles arise. Valuation therefore fluctuates with developments in innovation and pipeline progress. A regulatory setback or pipeline failure is enough to trigger a sharp rerating.
Break down ALNY's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.